New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
07:47 EDTCARACara Therapeutics price target raised to $29 from $25 at Canaccord
Canaccord raised its price target on Cara Therapeutics to $29 from $25 on the CRS-45's potential in adjunct post-operative pain relief. The firm expects positive Phase 3 data in the second half of 2015 and could have potential US sales of $750M. Shares are Buy rated.
News For CARA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 29, 2014
09:19 EDTCARAOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Goodyear Tire (GT), up 10%... Electronic Arts (EA), up 3.7%... ZELTIQ (ZLTQ), up 9%... Eaton (ETN), up 2.3%... Anadarko (APC), up 2%... U.S. Steel (X), up 7.7%... IAC (IACI), up 3.6%. ALSO HIGHER: Fiat Chrysler (FCAU), up 12% after reporting quarterly results, announcing plan to spin off Ferrari... Cara Therapeutics (CARA), up 17.8% after HAL trial of IV formulation of CR845 met primary endpoint... Jamba (JMBA), up 4% after upgraded at Wedbush. DOWN AFTER EARNINGS: Facebook (FB), down 5.7%... Gilead (GILD), down 3.2%... Ralph Lauren (RL), down 2.3%... SodaStream (SODA), down 3%... Garmin (GRMN), down 5%... Applied Micro Circuits (AMCC), down 9.9%... STMicroelectronics (STM), down 10%... Ballard Power (BLDP), down 8.7%... Hershey (HSY), down 3.3%... Deutsche Bank (DB), down 2.3%... McKesson (MCK), down 2%. ALSO LOWER: Sanofi (SNY), down 5.7% after downgraded at various firms including Barclays and BofA/Merrill after the company's board removed Christopher Viehbacher as CEO... InvenSense (INVN), down 22%, downgraded at Pacific Crest, Northland and Piper Jaffray following the company's Q2 earnings results... CareTrust REIT (CTRE), down 3.6% after acquiring Cross Healthcare Seniors housing portfolio... Orbital (ORB), down 16% after Orb-3 launch mishap... American Realty (ARCP), down 22% after announcing resignations of CFO, CAO.
08:14 EDTCARACara Therapeutics to host conference call
Conference call to discuss positive results from Human Abuse Liability Trial of Peripheral Opioid for Acute Pain, I.V. CR845 will be held on October 29 at 9 am. Webcast Link
07:13 EDTCARACara Therapeutics HAL trial of IV formulation of CR845 met primary endpoint
Cara Therapeutics announced positive results from its Human Abuse Liability, or HAL, trial of an intravenous, or IV, formulation of CR845, a first-in-class peripherally-selective kappa opioid agonist. Top-line results showed that therapeutic and supratherapeutic doses of I.V. CR845 met the trial's primary endpoint by demonstrating highly statistically significant lower "drug liking" scores as measured by visual analog scale, or VAS, Emax when compared to I.V. pentazocine, a Schedule IV opioid receptor agonist. I.V. CR845 also demonstrated highly statistically significant lower "feeling high" and "overall liking" scores as compared to pentazocine. Additionally, both doses of I.V. CR845 were rated equivalent to placebo on "overall drug liking" and "take drug again" measures. "Drug liking," "feeling high," "overall liking" and "take drug again" scores are standard subjective measures recommended by the FDA to assess a drug's abuse liability, both for recommended scheduling as well as labeling.
06:59 EDTCARACara Therapeutics trading halted, pending news
Subscribe for More Information
October 27, 2014
08:47 EDTCARACara Therapeutics announces unexpected death of Chief Medical Officer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use